246* What is the level of understanding about nebuliser therapy in patients attending an adult cystic fibrosis clinic?  by Lloyd, E. et al.
S62 8. Physiotherapy
244* Inﬂuence of inhaled hypertonic saline (NaCl 6%) before or
during autogenic drainage on sputum weight, oxygen saturation,
heart frequency and dyspnoea in cystic ﬁbrosis patients
F. Van Ginderdeuren1, S. Vanlaethem1, H. Eyns1, I. De Schutter1, E. Dewachter1,
A. Malfroot1. 1UZ Brussel, CF Clinic, Brussels, Belgium
Background: Inhalation of hypertonic saline 6% (HS) improves mucociliary
transport on short time basis in CF patients and is also proven to be a safe and
low cost intervention. Autogenic Drainage (AD) is an effective airway clearance
technique, experienced as very comfortable by CF patients. The aim of this study
is to evaluate the efﬁcacy of an AD treatment combined with inhalation of HS. It
will also be examined if it is more efﬁcient to inhale the HS before or during the
AD session, and if the interventions are safe and comfortable.
Methods: In this randomized, clinical cross-over study, 12 hospitalised CF patients
>14yrs of age, received 3 therapy regimens in 3 consecutive days: inhalation of
HS (4ml of NaCl 6%) during AD (30min), inhalation of HS (4ml of NaCl 6%)
before AD (HS pre AD), and AD only (30min). Before and after each session,
oxygen saturation (SaO2), heart frequency (HF) and dyspnoea were measured and
wet sputum was collected and weighed.
Results: Patients signiﬁcantly coughed up more sputum during treatments where
AD was combined with HS (“AD+HS” and “HS pre AD”) compared to the AD
treatment without HS (respectively 20.4±9.6 and 20.6± vs. 15.2±9.3 g; respectively
p = 0.01 and p = 0.028). There was no signiﬁcant difference in wet sputum weight
between “HS+AD” and “HS pre AD” (p = 0.942). For SaO2, HF and dyspnoea, no
signiﬁcant differences were found before and after treatments.
Conclusion: By inhaling HS during AD, the duration of treatment can be shortened
and the compliance improved without a loss of efﬁciency in sputum clearance. This
intervention has proven to be safe and comfortable.
245 Audit of accepted hypertonic saline concentration in children
with cystic ﬁbrosis
M. Ma˚rtensson1, P. Meyer1. 1Ska˚ne University Hospital, CF Centre, Lund, Sweden
Background: Nebulized HS is increasingly used as mucus loosener in children
with CF. The optimal HS dosage, concentration and millilitres nebulized are not
known. It’s described in literature that acceptance and reported side effects are
related to increased HS concentration. The most common and the recommended
HS concentration is 7%. Our primary aim was for the patients to accept 5ml with
a 5% HS concentration. If not tolerated we intended to try a lower concentration.
The introduction and acceptance training would be part of a routine policlinic visit
at the physiotherapist.
Objective: To audit the accepted HS concentration in the 34 patients >2 years and
<18 years that we intended to treat with HS.
Method: The HS concentration used at the last visit in 2010 was collected from the
medical records from the 34 patients on HS treatment. The patients where treated
with HS >2 months.
Results: 16/34 patients accepted and completed the treatment. All nebulized 5ml
and reported a positive effect. 5% HS was accepted by 9/16, only 1/16 accepted
7% HS, 2/16 accepted 4% HS, 4/16 accepted 3% HS. 18/34 did not tolerate
HS and therefore did not complete the treatment. The achieved acceptance level
concentration was in average 4.75% HS.
Conclusion: Only 47% accepted the HS treatment, even when starting with 5%
HS concentration or lower. Our audit showed a lower HS concentration than
intended and recommended but still with a reported good mucus loosening effect.
We intend to modify and hopefully improve HS acceptability even with a higher
HS concentration and maybe a greater volume. Further work needs to be done to
establish the optimum concentration and volume of nebulized HS.
246* What is the level of understanding about nebuliser therapy in
patients attending an adult cystic ﬁbrosis clinic?
E. Lloyd1, J. Park1, M.J. Walshaw1, J. Greenwood1, M.J. Ledson1. 1Liverpool
Heart and Chest Hospital, Liverpool, United Kingdom
Introduction: Although nebulised therapy is an important part of the management
of CF patients, it is time consuming and patients may adhere poorly to prescribed
regimen. To study this further, we explored the understanding of and attitudes
towards nebuliser therapy in our CF patients, including barriers to adherence.
Method: Seventy consecutive adult CF patients (50 mild/moderate disease only,
36 male) completed a structured questionnaire looking at their knowledge of
infection status, drugs prescribed, nebuliser use, and adherence.
Results: 53 (75%) knew they were infected with Pseudomonas species, 9 (13%)
other organisms, 2 (3%) thought they had no organisms but 6 (9%) were unsure. Of
the 64 who were prescribed at least one nebulised drug, 7 (10%) did not know the
name(s) and 10 (14%) the dose. As regards adherence, 18 (26%) admitted missing
doses daily and a further 10 (14%) did not respond. However, 46 (66%) stated
that doses were missed due to a busy lifestyle (20, 44%), unnecessary therapy (15,
33%), and burden of care (4, 9%). As regards knowledge of the nebulised drugs
themselves, only 40 of 55 using antibiotics, 29 of 47 using mucolytics and 31 of
55 using bronchodilators had a clear understanding. Half the patients were unaware
of possible side-effects. Only two thirds nebulised mucolytics and bronchodilators
before, and 58% antibiotics after, employing airway clearance techniques.
Conclusions: While some of our patients show good understanding and adherence
to nebulised drugs, many have little knowledge in all the parameters surveyed. As
a team we need to review our practice in relation to patient education about this
important aspect of their care.
247 The tolerability of nebulised meropenem within an adult cystic
ﬁbrosis centre
J. Parker-Stafford1, V. Gettins1, A. Jones1, S. Johnson1, A. Brennan1. 1Manchester
Adult CF Centre, University Hospital of South Manchester, Manchester, United
Kingdom
Background: Meropenem (Mero) is a broad spectrum carbapenem that is used
to treat a wide range of Gram-negative and Gram-positive infections as well as
anaerobes and Pseudomonas aeruginosa (Ps.A). Whilst it is generally used in
IV form, its use in an unlicensed nebulised form may provide an alternative
maintenance treatment for patients with CF who are deteriorating.
Aim: To establish if nebulised Mero is tolerated and its affect on FEV1% predicted
for patients with CF.
Methods: Records of 18 patients who had received nebulised Mero were examined
for: age, microbiological group, strength of dose and duration of use. A variety of
conventional and AAD nebuliser devices were used. The best FEV1% predicted
in the 3 months pre and post challenge was analysed. All patients received a 250
or 500mg dose of Mero (reconstituted with WFI) preceded with a bronchodilator.
Side effects were documented.
Results: 18 patients, mean (SD) age 27.4 (6.2), with a mean predicted FEV1 =
43.7% (23.1), with Burkholderia cepacia (B.Cep) (n = 14), Ps.A (n = 3) or Non Ps.A
(n = 1) received nebulised Mero (n = 8,250mg, n = 10,500mg) for a mean duration
of 63 weeks (72).
FEV1% predicted 3/12 pre Mero = 43.7 (23.1), post = 45.5 (22.2), p = 0.45.
7 patients did not have complete data for 3/12 Mero use: 2 due to timing of data
collection, 1 due to adherence, 1 with no perceived beneﬁts and 3 due to tightness
(1 following a 500mg then 250mg dose, 1 with 250mg only and 1 with 500mg
only).
Conclusion: The majority of patients given Mero following a deterioration of health
reported no side effects. Nebulised Mero is generally well tolerated in the majority
of subjects with CF including those with severe lung disease.
